Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Siegel

Showing results (1-10 of 100) with videos related to

Pageof 10
Sort By:
Oncology (Williston Park, N.Y.)|September 4, 2014
Managing adverse events of multiple myeloma and anti-multiple myeloma treatment: a perspective on carfilzomibDavid S Siegel
Therapeutic Advances in Hematology|December 10, 2013
From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myelomaDavid S Siegel
Seminars in Hematology|June 26, 2012
Relapsed/Refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistanceDavid S Siegel
Haematologica|August 2, 2014
Reply to "The challenge of cross-trial comparison using limited data" Haematologica. 2014;99(8):e000David S Siegel
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 24, 2014
Pretransplant induction regimens for multiple myelomaDavid H Vesole, David S Siegel
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Counterpoints: Do patients with multiple myeloma need maintenance treatment? No, maintenance treatment should not be used outside clinical trialsDavid H Vesole, David S Siegel
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Regulation of NF-kB in multiple myeloma: therapeutic implicationsRena Feinman, David S Siegel, James Berenson
The Lancet. Haematology|December 4, 2018
The forgotten class of drugs for multiple myeloma: HDAC inhibitorsNoa Biran, David S Siegel, David H Vesole
Clinical Advances in Hematology & Oncology : H&O|September 20, 2011
Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myelomaDavid S Siegel, Ravi Vij, Andrzej J Jakubowiak
Journal of Hematology & Oncology|July 2, 2016
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myelomaLarysa Sanchez, Yucai Wang, David S Siegel, et al.
Pageof 10

Showing results (1-10 of 100) with videos related to

Sort By:
Pageof 10
Oncology (Williston Park, N.Y.)|September 4, 2014
Managing adverse events of multiple myeloma and anti-multiple myeloma treatment: a perspective on carfilzomibDavid S Siegel
Therapeutic Advances in Hematology|December 10, 2013
From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myelomaDavid S Siegel
Seminars in Hematology|June 26, 2012
Relapsed/Refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistanceDavid S Siegel
Haematologica|August 2, 2014
Reply to "The challenge of cross-trial comparison using limited data" Haematologica. 2014;99(8):e000David S Siegel
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 24, 2014
Pretransplant induction regimens for multiple myelomaDavid H Vesole, David S Siegel
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Counterpoints: Do patients with multiple myeloma need maintenance treatment? No, maintenance treatment should not be used outside clinical trialsDavid H Vesole, David S Siegel
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Regulation of NF-kB in multiple myeloma: therapeutic implicationsRena Feinman, David S Siegel, James Berenson
The Lancet. Haematology|December 4, 2018
The forgotten class of drugs for multiple myeloma: HDAC inhibitorsNoa Biran, David S Siegel, David H Vesole
Clinical Advances in Hematology & Oncology : H&O|September 20, 2011
Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myelomaDavid S Siegel, Ravi Vij, Andrzej J Jakubowiak
Journal of Hematology & Oncology|July 2, 2016
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myelomaLarysa Sanchez, Yucai Wang, David S Siegel, et al.
Pageof 10